Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain†Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital. This Phase II study builds upon Alzamend's prior "Lithium in Brain" clinical trial in healthy subjects, for which the clinical portion was completed in November 2025. Topline data from that study are expected by the end of March 2026. Following completion in healthy volunteers, Alzamend and MGH are now expanding the program to subjects with ...

Core Insights - Alzamend Neuro, Inc. has initiated the first of five Phase II clinical studies for AL001, targeting conditions such as Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [1][2] - The study aims to demonstrate AL001's effectiveness in delivering lithium more efficiently to the brain while reducing systemic side effects compared to traditional lithium salts [2][3] Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [6] - The company's pipeline includes two main candidates: AL001, a novel lithium-delivery system, and ALZN002, a cell-based therapeutic vaccine aimed at combating Alzheimer's [6][8] Product Details - AL001 is designed to provide the benefits of marketed lithium salts while minimizing toxicities, potentially eliminating the need for therapeutic drug monitoring [5][3] - Previous studies indicate that AL001 allows for better brain absorption of lithium while maintaining lower blood levels, which could lead to safer treatment options [2][5] Market Potential - The introduction of AL001 could significantly enhance treatment outcomes for over 43 million Americans suffering from the targeted conditions, potentially reshaping current treatment paradigms [4][3] - By addressing the complexities associated with traditional lithium therapies, AL001 may improve patient quality of life and adherence to treatment [3][4] Future Developments - Topline data from the ongoing studies is expected by the end of the year, with head-to-head comparisons planned against a marketed lithium carbonate product [7]